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I. INTRODUCTION
These guidelines represent an update of those published in
1996 and are intended for physicians who are involved in
the preoperative, operative, and postoperative care of pa-
tients undergoing noncardiac surgery. They provide a
framework for considering cardiac risk of noncardiac surgery
in a variety of patient and surgical situations. The overriding
theme of these guidelines is that preoperative intervention is
rarely necessary simply to lower the risk of surgery unless
such intervention is indicated irrespective of the preopera-
tive context. The purpose of preoperative evaluation is not
simply to give medical clearance but rather to perform an
evaluation of the patient’s current medical status; make
recommendations concerning the evaluation, management,
and risk of cardiac problems over the entire perioperative
period; and provide a clinical risk profile that the patient,
primary physician, anesthesiologist, and surgeon can use in
making treatment decisions that may influence short- and
long-term cardiac outcomes. The goal of the consultation is
to identify the most appropriate testing and treatment
strategies to optimize care of the patient, provide assessment
of both short- and long-term cardiac risk, and avoid
unnecessary testing in this era of cost containment.
A. Development of Guidelines
These guidelines are based on an update of a Medline,
EMBASE, Cochrane library, and Best Evidence search of
the English literature from 1995 through 2000, a review of
selected journals, and the expert opinions of 12 committee
members representing various disciplines of cardiovascular
care, including general cardiology, interventional cardiology,
noninvasive testing, vascular medicine, vascular surgery,
anesthesiology, and arrhythmia management. As a result of
these searches, more than 400 relevant new articles were
identified. In addition, draft guidelines were submitted for
critical review and amendment to the executive officers
representing the American College of Cardiology (ACC)
and the American Heart Association (AHA).
A large proportion of the data used to develop these
guidelines are based on observational or retrospective studies
or knowledge of management of cardiovascular disorders in
the nonoperative setting. Although the collective body of
knowledge about the identification of high- and low-risk
patients by perioperative clinical and noninvasive evaluation
is substantial, the number of prospective or randomized
studies that have been performed to establish the value of
different treatments on perioperative outcomes is small. The
ACC/AHA classifications of evidence used in this report to
summarize the indication for a particular therapy or treat-
ment are as follows:
Class I: Conditions for which there is evidence
and/or general agreement that a given proce-
dure/therapy is useful and effective.
Class II: Conditions for which there is conflicting
evidence and/or a divergence of opinion
about the usefulness/efficacy of performing
the procedure/therapy.
Class IIa: Weight of evidence/opinion is in
favor of usefulness/efficacy.
Class IIb: Usefulness/efficacy is less well es-
tablished by evidence/opinion.
Class III: Conditions for which there is evidence
and/or general agreement that a procedure/
therapy is not useful/effective and in some
cases may be harmful.
Two versions of the full-text guidelines are available on
the World Wide Web sites of both the American College of
Cardiology (www.acc.org) and the American Heart Asso-
ciation (www.americanheart.org); one version highlights the
updated material (deleted text in strikeout and new text in
red), and the other fully incorporates the changes. This
document was approved for publication by the governing
bodies of the ACC and the AHA, will be reviewed annually
by the Task Force, and will be considered current unless the
Task Force revises or withdraws them from distribution.
B. General Approach
The preoperative cardiac evaluation must be carefully tai-
lored to the circumstances that have prompted the consul-
tation and to the nature of the surgical illness (e.g., acute
surgical emergency) as opposed to urgent or elective cases.
Successful perioperative evaluation and treatment of cardiac
patients undergoing noncardiac surgery requires careful
teamwork and communication between the patient, primary
care physician, anesthesiologist, consultant, and surgeon. In
general, indications for further cardiac testing and treat-
ments are the same as those in the nonoperative setting, but
their timing is dependent on such factors as the urgency of
noncardiac surgery, the patient’s risk factors, and specific
surgical considerations. Coronary revascularization before
noncardiac surgery to enable the patient to “get through” the
noncardiac procedure is appropriate only for a small subset
of patients at very high risk. Preoperative testing should be
limited to circumstances in which the results will affect
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patient treatment and outcomes. A conservative approach to
the use of expensive tests and treatments is recommended.
C. Preoperative Clinical Evaluation
The initial history, physical examination, and electrocardio-
gram (ECG) assessment should focus on identification of
potentially serious cardiac disorders, including coronary
artery disease (CAD) [e.g., prior myocardial infarction (MI)
and angina pectoris], heart failure (HF), symptomatic ar-
rhythmias, presence of pacemaker or implantable cardio-
verter defibrillator (ICD), or a history of orthostatic intol-
erance (1). The presence of anemia may also place a patient
at higher perioperative risk (2–4).
In addition to identifying the presence of pre-existing
manifested heart disease, it is essential to define disease
severity, stability, and prior treatment. Other factors that
help determine cardiac risk include functional capacity, age,
comorbid conditions (e.g., diabetes mellitus, peripheral
vascular disease, renal dysfunction, and chronic pulmonary
disease), and type of surgery (vascular procedures and
prolonged, complicated thoracic, abdominal, and head and
neck procedures are considered higher risk).
Numerous risk indices have been developed over the past
25 years on the basis of multivariate analyses (5–14). In
addition to the presence of CAD and HF, a history of
cerebrovascular disease, preoperative elevated creatinine
greater than 2 mg per deciliter, insulin treatment for
diabetes mellitus, and high-risk surgery have all been
associated with increased perioperative cardiac morbidity.
Despite these risk indices, there was consensus among the
committee members to place clinical risk factors into 3
categories of predictors (see Section II-A).
II. FURTHER PREOPERATIVE
TESTING TO ASSESS CORONARY RISK
Which patients are most likely to benefit from preoperative
coronary assessment and treatment? The lack of adequately
controlled or randomized clinical trials to define the optimal
evaluation strategy led to the proposed algorithm based on
collected observational data and expert opinion (see Fig. 1).
Since publication of the guidelines in 1996, several studies
have suggested that this stepwise approach to the assess-
ment of CAD is both efficacious and cost-effective.
A stepwise bayesian strategy that relies on assessment of
clinical markers, prior coronary evaluation and treatment,
functional capacity, and surgery-specific risk is outlined in
Figure 1. A framework for determining which patients are
candidates for cardiac testing is presented in algorithmic
form. Successful use of the algorithm requires an apprecia-
tion of the different levels of risk attributable to certain
clinical circumstances, levels of functional capacity, and
types of surgery. These are defined below, after which the
algorithm is reviewed step by step.
A. Clinical Markers
The major clinical predictors (Table 1) of increased periop-
erative cardiovascular risk are a recent unstable coronary
syndrome such as an acute MI (documented MI less than 7
days previously), recent MI (more than 7 days but less than
1 month before surgery), unstable or severe angina, evidence
of a large ischemic burden by clinical symptoms or nonin-
vasive testing, decompensated HF, significant arrhythmias
(high-grade atrioventricular block, symptomatic arrhyth-
mias in the presence of underlying heart disease, or su-
praventricular arrhythmias with uncontrolled ventricular
rate), and severe valvular disease.
Intermediate predictors of increased risk are mild angina
pectoris, a more remote prior MI (more than 1 month
before planned surgery), compensated HF, preoperative
creatinine greater than or equal to 2.0 mg per deciliter, and
diabetes mellitus. Minor predictors of risk are advanced age,
abnormal ECG, rhythm other than sinus, low functional
capacity, history of stroke, and uncontrolled systemic hy-
pertension.
A history of MI or abnormal Q waves by ECG is listed
as an intermediate predictor, whereas an acute MI (defined
as at least 1 documented MI less than or equal to 7 days
before the examination) or recent MI (more than 7 days but
less than or equal to 1 month before the examination) with
evidence of important ischemic risk by clinical symptoms or
noninvasive study is a major predictor. This definition
reflects the consensus of the ACC Cardiovascular Database
Committee. In this way, the separation of MI into the
traditional 3- and 6-month intervals has been avoided
(6,15). Current management of MI provides for risk strat-
ification during convalescence (16). If a recent stress test
does not indicate residual myocardium at risk, the likelihood
of reinfarction after noncardiac surgery is low. Although
there are no adequate clinical trials on which to base firm
recommendations, it appears reasonable to wait 4 to 6 weeks
after MI to perform elective surgery.
B. Functional Capacity
Functional capacity can be expressed in metabolic equiva-
lent (MET) levels (Table 2). Multiples of the baseline MET
value can be used to express aerobic demands for specific
activities. Perioperative cardiac and long-term risks are
increased in patients unable to meet a 4-MET demand
during most normal daily activities (17–19). The Duke
Activity Status Index and other activity scales provide the
clinician with a set of questions to determine a patient’s
functional capacity (20–22). Energy expenditures for activ-
ities such as eating, dressing, walking around the house, and
dishwashing range from 1 to 4 METs. Climbing a flight of
stairs, walking on level ground at 6.4 km per hour, running
a short distance, scrubbing floors, or playing a game of golf
represents 4 to 10 METs. Strenuous sports such as swim-
ming, singles tennis, and football often exceed 10 METs.
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Figure 1. Stepwise approach to preoperative cardiac assessment. Steps are discussed in text. *Subsequent care may include cancellation or delay of surgery,
coronary revascularization followed by noncardiac surgery, or intensified care.
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C. Surgery-Specific Risk
Surgery-specific cardiac risk of noncardiac surgery is related
to 2 important factors: the type of surgery itself and the
degree of hemodynamic stress associated with the proce-
dures. The duration and intensity of coronary and myocar-
dial stressors can be helpful in estimating the likelihood of
perioperative cardiac events, particularly for emergency sur-
gery. Surgery-specific risk for noncardiac surgery can be
stratified as high, intermediate, and low (Table 3) (23).
High-risk surgery includes major emergency surgery, par-
ticularly in the elderly; aortic and other major vascular
surgery; peripheral vascular surgery; and anticipated pro-
longed procedures associated with large fluid shifts and/or
blood loss. Intermediate-risk procedures include intraperi-
toneal and intrathoracic surgery, carotid endarterectomy,
head and neck surgery, orthopedic surgery, and prostate
surgery. Low-risk procedures include endoscopic and super-
ficial procedures, cataract surgery, and breast surgery.
The following steps correspond to the algorithm pre-
sented in Figure 1.
Step 1
What is the urgency of noncardiac surgery? Certain
emergencies do not allow time for preoperative cardiac
evaluation. Postoperative risk stratification may be appro-
priate for some patients who have not had such an assess-
ment before.
Step 2
Has the patient undergone coronary revascularization in
the past 5 years? If so, and if clinical status has remained
stable without recurrent symptoms/signs of ischemia, fur-
ther cardiac testing is generally not necessary (24).
Step 3
Has the patient had a coronary evaluation in the past 2
years? If coronary risk was adequately assessed and the
findings were favorable, it is usually not necessary to repeat
testing unless the patient has experienced a change or new
symptoms of coronary ischemia since the previous evalua-
tion.
Step 4
Does the patient have an unstable coronary syndrome or
a major clinical predictor of risk? When elective noncardiac
surgery is being considered, the presence of unstable coro-
nary disease, decompensated HF, symptomatic arrhythmias,
and/or severe valvular heart disease usually leads to cancel-
lation or delay of surgery until the problem has been
identified and treated.
Step 5
Does the patient have intermediate clinical predictors of
risk? The presence or absence of prior MI by history or
ECG, angina pectoris, compensated or prior HF, preoper-
ative creatinine greater than or equal to 2 mg per deciliter,
Table 1. Clinical Predictors of Increased Perioperative
Cardiovascular Risk (Myocardial Infarction, Heart Failure,
Death)
Major
Unstable coronary syndromes
• Acute or recent myocardial infarction* with evidence of important
ischemic risk by clinical symptoms or noninvasive study
• Unstable or severe† angina (Canadian class III or IV)‡
Decompensated heart failure
Significant arrhythmias
• High-grade atrioventricular block
• Symptomatic ventricular arrhythmias in the presence of underlying
heart disease
• Supraventricular arrhythmias with uncontrolled ventricular rate
Severe valvular disease
Intermediate
Mild angina pectoris (Canadian class I or II)
Previous myocardial infarction by history or pathological Q waves
Compensated or prior heart failure
Diabetes mellitus (particularly insulin-dependent)
Renal insufficiency
Minor
Advanced age
Abnormal ECG (left ventricular hypertrophy, left bundle-branch block,
ST-T abnormalities)
Rhythm other than sinus (e.g., atrial fibrillation)
Low functional capacity (e.g., inability to climb one flight of stairs with
a bag of groceries)
History of stroke
Uncontrolled systemic hypertension
ECG indicates electrocardiogram.
*The American College of Cardiology National Database Library defines recent
MI as greater than 7 days but less than or equal to 1 month (30 days); acute MI is
within 7 days.
†May include “stable” angina in patients who are unusually sedentary.
‡Campeau L. Grading of angina pectoris. Circulation. 1976;54:522–523.
Table 2. Estimated Energy Requirements for Various Activities*
1 MET Can you take care of yourself? 4 METs Climb a flight of stairs or walk up a hill?
Eat, dress, or use the toilet? Walk on level ground at 4 mph or 6.4 km per h?
Walk indoors around the house? Run a short distance?
Walk a block or two on level
ground at 2 to 3 mph or 3.2
to 4.8 km per h?
Do heavy work around the house like scrubbing
floors or lifting or moving heavy furniture?
Participate in moderate recreational activities like
4 METs
Do light work around the house
like dusting or washing dishes?
golf, bowling, dancing, doubles tennis, or
throwing a baseball or football?
Greater than
10 METs
Participate in strenuous sports like swimming,
singles tennis, football, basketball, or skiing?
MET indicates metabolic equivalent.
*Adapted from the Duke Activity Status Index (20) and AHA Exercise Standards (96).
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and/or diabetes mellitus helps to further stratify clinical risk
for perioperative coronary events. Consideration of func-
tional capacity and level of surgery-specific risk allows a
rational approach to identify patients most likely to benefit
from further noninvasive testing.
Step 6
Patients without major but with intermediate predictors
of clinical risk and moderate or excellent functional capacity
can generally undergo intermediate-risk surgery with little
likelihood of perioperative death or MI. Conversely, further
noninvasive testing is often considered for patients with
poor functional capacity or moderate functional capacity but
higher-risk surgery, especially for patients with 2 or more
intermediate predictors of risk.
Step 7
Noncardiac surgery is generally safe for patients with
neither major nor intermediate predictors of clinical risk and
moderate or excellent functional capacity (4 METs or
greater). Additional testing may be considered on an indi-
vidual basis for patients without clinical markers but with
poor functional capacity who are facing higher-risk opera-
tions, particularly those with several minor clinical predic-
tors of risk who are scheduled to undergo vascular surgery.
Step 8
The results of noninvasive testing can be used to deter-
mine the need for additional preoperative testing and
treatment. In some patients with documented CAD, the
risk of coronary intervention or corrective cardiac surgery
may approach or even exceed the risk of the proposed
noncardiac surgery. This approach may be appropriate,
however, if it significantly improves the patient’s long-term
prognosis.
For some patients, a careful consideration of clinical,
surgery-specific, and functional status attributes leads to a
decision to proceed to coronary angiography.
III. MANAGEMENT OF SPECIFIC
PREOPERATIVE CARDIOVASCULAR CONDITIONS
A. Hypertension
Stage 3 hypertension (systolic blood pressure greater than or
equal to 180 mm Hg and diastolic blood pressure greater
than or equal to 110 mm Hg) should be controlled before
surgery. In many such instances, establishment of an effec-
tive regimen can be achieved over several days to weeks of
preoperative outpatient treatment. If surgery is more urgent,
rapid-acting agents can be administered that allow effective
control in a matter of minutes or hours. Beta-blockers
appear to be particularly attractive agents. Continuation of
preoperative antihypertensive treatment through the peri-
operative period is critical.
B. Valvular Heart Disease
Indications for evaluation and treatment of valvular heart
disease are identical to those in the nonpreoperative setting.
Symptomatic stenotic lesions are associated with risk of
perioperative HF or shock and often require percutaneous
valvotomy or valve replacement before noncardiac surgery to
lower cardiac risk (6,25–27). Symptomatic regurgitant valve
disease is usually better tolerated perioperatively and may be
stabilized preoperatively with intensive medical therapy and
monitoring. Regurgitant valve disease can then be treated
definitively with valve repair or replacement after noncardiac
surgery. Medical therapy and monitoring are appropriate
when a delay of several weeks or months before noncardiac
surgery may have severe consequences. Exceptions may
include severe valvular regurgitation with reduced left ven-
tricular function, in which overall hemodynamic reserve is
so limited that destabilization during perioperative stresses
is likely.
C. Myocardial Disease
Dilated and hypertrophic cardiomyopathy are associated
with an increased incidence of perioperative HF (6,28,29).
Management is aimed at maximizing preoperative hemody-
namic status and providing intensive postoperative medical
therapy and surveillance. An estimate of hemodynamic
reserve is useful for anticipating potential complications
from intraoperative or postoperative stress.
D. Arrhythmias and Conduction Abnormalities
The presence of an arrhythmia or cardiac conduction
disturbance should provoke a careful evaluation for under-
lying cardiopulmonary disease, drug toxicity, or metabolic
abnormality. Therapy should be initiated for symptomatic
or hemodynamically significant arrhythmias, first to reverse
an underlying cause and second to treat the arrhythmia.
Indications for antiarrhythmic therapy and cardiac pacing
are identical to those in the nonoperative setting. Frequent
ventricular premature beats and/or asymptomatic nonsus-
tained ventricular tachycardia have not been associated with
an increased risk of nonfatal MI or cardiac death in the
Table 3. Cardiac Risk* Stratification for Noncardiac Surgical
Procedures
High (Reported cardiac risk often greater than 5%)
• Emergent major operations, particularly in the elderly
• Aortic and other major vascular surgery
• Peripheral vascular surgery
• Anticipated prolonged surgical procedures associated with large fluid
shifts and/or blood loss
Intermediate (Reported cardiac risk generally less than 5%)
• Carotid endarterectomy
• Head and neck surgery
• Intraperitoneal and intrathoracic surgery
• Orthopedic surgery
• Prostate surgery
Low† (Reported cardiac risk generally less than 1%)
• Endoscopic procedures
• Superficial procedure
• Cataract surgery
• Breast surgery
*Combined incidence of cardiac death and nonfatal myocardial infarction.
†Do not generally require further preoperative cardiac testing.
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perioperative period (30,31), and therefore, aggressive mon-
itoring or treatment in the perioperative period generally is
not necessary.
E. Implantable Pacemakers or ICDs
The type and extent of evaluation of a pacemaker or ICD
depend on the urgency of the surgery, whether a pacemaker
has unipolar or bipolar leads, whether electrocautery is
bipolar or unipolar, the distance between electrocautery and
pacemaker, and pacemaker dependency. ICD devices
should be programmed off immediately before surgery and
then on again postoperatively.
IV. SUPPLEMENTAL PREOPERATIVE EVALUATION
Specific recommendations for supplemental preoperative
evaluation must be individualized to each patient and
circumstance. The following may be appropriate in specific
situations: assessment of resting left ventricular function,
exercise stress testing, pharmacological stress testing, am-
bulatory ECG monitoring, and coronary angiography. In
most ambulatory patients, the test of choice is exercise ECG
testing, which can both provide an estimate of functional
capacity and detect myocardial ischemia through changes in
the ECG and hemodynamic response. In patients with
important abnormalities on their resting ECG (e.g., left
bundle-branch block, left ventricular hypertrophy with
strain pattern, or digitalis effect), other techniques such as
exercise echocardiography or exercise myocardial perfusion
imaging should be considered. Recommendations regarding
individual testing modalities are given below.
A. Resting Left Ventricular Function
Resting left ventricular function has not been found to be a
consistent predictor of perioperative ischemic events (32–40).
Recommendations for Preoperative Noninvasive Evalu-
ation of Left Ventricular Function
Class I
Patients with current or poorly controlled HF. (If
previous evaluation has documented severe left ven-
tricular dysfunction, repeat preoperative testing may
not be necessary).
Class IIa
Patients with prior HF and patients with dyspnea of
unknown origin.
Class III
As a routine test of left ventricular function in patients
without prior HF.
B. 12-Lead ECG
The resting 12-lead ECG does not identify increased
perioperative risk in patients undergoing low-risk surgery,
but certain ECG abnormalities are clinical predictors of
increased perioperative and long-term cardiovascular risk in
clinically intermediate- and high-risk patients (41–45).
Recommendations for Preoperative 12-Lead Rest ECG
Class I
Recent episode of chest pain or ischemic equivalent in
clinically intermediate- or high-risk patients scheduled
for an intermediate- or high-risk operative procedure.
Class IIa
Asymptomatic persons with diabetes mellitus.
Class IIb
1. Patients with prior coronary revascularization.
2. Asymptomatic male more than 45 years old or
female more than 55 years old with 2 or more
atherosclerotic risk factors.
3. Prior hospital admission for cardiac causes.
Class III
As a routine test in asymptomatic subjects undergoing
low-risk operative procedures.
C. Exercise or Pharmacological Stress Testing
Recommendations for Exercise or Pharmacological
Stress Testing
Class I
1. Diagnosis of adult patients with intermediate pre-
test probability of CAD.
2. Prognostic assessment of patients undergoing ini-
tial evaluation for suspected or proven CAD; eval-
uation of subjects with significant change in clinical
status.
3. Demonstration of proof of myocardial ischemia
before coronary revascularization.
4. Evaluation of adequacy of medical therapy; prog-
nostic assessment after an acute coronary syndrome
(if recent evaluation unavailable).
Class IIa
Evaluation of exercise capacity when subjective assess-
ment is unreliable.
Class IIb
1. Diagnosis of CAD patients with high or low pretest
probability: those with resting ST depression less
than 1 mm, those taking digitalis therapy, or those
with ECG criteria for left ventricular hypertrophy.
2. Detection of restenosis in high-risk asymptomatic
subjects within the initial months after percutane-
ous coronary intervention (PCI).
Class III
1. For exercise stress testing, diagnosis of patients with
resting ECG abnormalities that preclude adequate
assessment, e.g., pre-excitation syndrome, electron-
ically paced ventricular rhythm, rest ST depression
greater than 1 mm, or left bundle-branch block.
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2. Severe comorbidity likely to limit life expectancy or
candidacy for revascularization.
3. Routine screening of asymptomatic men or women.
4. Investigation of isolated ectopic beats in young
patients.
D. Coronary Angiography
Recommendations for Coronary Angiography in Periop-
erative Evaluation Before (or After) Noncardiac Surgery
Class I: Patients With Suspected or Known CAD
1. Evidence for high risk of adverse outcome based on
noninvasive test results.
2. Angina unresponsive to adequate medical therapy.
3. Unstable angina, particularly when facing inter-
mediate-risk* or high-risk* noncardiac surgery.
4. Equivocal noninvasive test results in patients at
high clinical risk† undergoing high-risk* surgery.
Class IIa
1. Multiple markers of intermediate clinical risk† and
planned vascular surgery (noninvasive testing
should be considered first).
2. Moderate to large ischemia on noninvasive testing
but without high-risk features and lower left ven-
tricular ejection fraction.
3. Nondiagnostic noninvasive test results in patients
at intermediate clinical risk† undergoing high-risk*
noncardiac surgery.
4. Urgent noncardiac surgery while convalescing from
acute MI.
Class IIb
1. Perioperative MI.
2. Medically stabilized class III or IV angina and
planned low-risk or minor* surgery.
Class III
1. Low-risk* noncardiac surgery with known CAD
and no high-risk results on noninvasive testing.
2. Asymptomatic after coronary revascularization with
excellent exercise capacity (greater than or equal to
7 METs).
3. Mild stable angina with good left ventricular func-
tion and no high-risk noninvasive test results.
4. Noncandidate for coronary revascularization owing
to concomitant medical illness, severe left ventric-
ular dysfunction (e.g., left ventricular ejection frac-
tion less than 0.20), or refusal to consider revascu-
larization.
5. Candidate for liver, lung, or renal transplant less
than 40 years old, as part of evaluation for trans-
plantation, unless noninvasive testing reveals high
risk for adverse outcome.
V. PERIOPERATIVE THERAPY OR
PREVIOUS CORONARY REVASCULARIZATION
A. Coronary Artery Bypass Grafting
Indications for coronary artery bypass grafting (CABG)
before noncardiac surgery are identical to those reviewed in
the ACC/AHA guidelines for CABG (46). CABG is rarely
indicated simply to “get a patient through” noncardiac
surgery. In patients enrolled in the Coronary Artery Surgery
Study (CASS) database, the cardiac risk associated with
noncardiac operations involving the thorax, abdomen, arte-
rial vasculature, and head and neck was reduced significantly
in those patients who had undergone prior CABG (23).
Patients undergoing elective noncardiac procedures who are
found to have prognostic high-risk coronary anatomy and in
whom long-term outcome would likely be improved by
CABG (47) should generally undergo revascularization
before a noncardiac elective surgical procedure of high or
intermediate risk (Table 3).
B. Percutaneous Coronary Intervention
There are no controlled trials comparing perioperative
cardiac outcome after noncardiac surgery for patients treated
with preoperative PCI versus medical therapy. Several small
observational series have suggested that cardiac death is
infrequent in patients who have undergone PCI before
noncardiac surgery (48–52). Several studies have also dem-
onstrated a number of complications from angioplasty,
including emergency CABG in some patients. Until further
data are available, indications for PCI in the perioperative
setting are similar to those in the ACC/AHA guidelines for
use of PCI in general (53). There is uncertainty regarding
how much time should pass between PCI and noncardiac
procedures. Delaying surgery for at least 1 week after
balloon angioplasty to allow for healing of the vessel injury
has theoretical benefits. If a coronary stent is used, a delay of
at least 2 weeks and ideally 4 to 6 weeks should occur before
noncardiac surgery to allow 4 full weeks of dual antiplatelet
therapy and re-endothelialization of the stent to be com-
pleted, or nearly so (54).
VI. PERIOPERATIVE MEDICAL THERAPY
Several recent trials have examined the impact of medical
therapy begun just before surgery on reducing cardiac
events. Two randomized, placebo-controlled trials of beta-
blocker administration have been performed (13,14,55,56).
*Cardiac risk according to type of noncardiac surgery. High risk: emergent major
operations, aortic and major vascular, peripheral vascular, anticipated prolonged
surgical procedure associated with large fluid shifts and blood loss; intermediate risk:
carotid endarterectomy, major head and neck, intraperitoneal and intrathoracic,
orthopedic, prostate; and low risk: endoscopic procedures, superficial procedures,
cataract, breast.
†Cardiac risk according to clinical predictors of perioperative death, MI, or heart
failure. High clinical risk: unstable angina, recent MI, and evidence of important
residual ischemic risk, decompensated heart failure, high degree of atrioventricular
block, symptomatic ventricular arrhythmias with known structural heart disease,
severe symptomatic valvular heart disease, patient with multiple intermediate risk
markers such as prior MI, heart failure, and diabetes; intermediate clinical risk: CCS
class I or II angina, prior MI by history or ECG, compensated or prior heart failure,
diabetes mellitus and renal insufficiency.
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One trial demonstrated reduced perioperative cardiac
events, and the other demonstrated improved 6-month
survival with perioperative beta-blocker usage. Several trials
have evaluated the utility of alpha-2 agonists, demonstrating
reduced cardiac event rates in the subset of patients with
known CAD undergoing vascular surgery (57–60).
There are still very few randomized trials of medical
therapy before noncardiac surgery to prevent perioperative
cardiac complications, and they do not provide enough data
from which to draw firm conclusions or recommendations.
Most are insufficiently powered to address the effect on
outcome of MI or cardiac death, and they rely on the
surrogate end point of ECG ischemia to show effect.
Current studies, however, suggest that appropriately admin-
istered beta-blockers reduce perioperative ischemia and may
reduce the risk of MI and death in high-risk patients. When
possible, beta-blockers should be started days or weeks
before elective surgery, with the dose titrated to achieve a
resting heart rate between 50 and 60 beats per minute.
Perioperative treatment with alpha-2 agonists may have
similar effects on myocardial ischemia, infarction, and car-
diac death. Clearly, this is an area in which further research
would be valuable.
Recommendations for Perioperative Medical Therapy
Class I
1. Beta-blockers required in the recent past to control
symptoms of angina or patients with symptomatic
arrhythmias or hypertension.
2. Beta-blockers: patients at high cardiac risk owing to
the finding of ischemia on preoperative testing who
are undergoing vascular surgery.
Class IIa
l. Beta-blockers: preoperative assessment identifies
untreated hypertension, known coronary disease, or
major risk factors for coronary disease.
Class IIb
1. Alpha-2 agonist: perioperative control of hyperten-
sion, or known CAD or major risk factors for CAD.
Class III
1. Beta-blockers: contraindication to beta-blockade.
2. Alpha-2 agonists: contraindication to alpha-2
agonists.
VII. ANESTHETIC CONSIDERATIONS
AND INTRAOPERATIVE MANAGEMENT
A. Anesthetic Agent
All anesthetic techniques and drugs have known cardiac
effects that should be considered in the perioperative plan.
There appears to be no one best myocardium-protective
anesthetic technique (61–65). Therefore, the choice of
anesthesia and intraoperative monitors is best left to the
discretion of the anesthesia care team, which will consider
the need for postoperative ventilation, cardiovascular effects
(including myocardial depression), sympathetic blockade,
and dermatomal level of the procedure. Advocates of mon-
itored anesthesia, in which local anesthesia is supplemented
by intravenous sedation/analgesia, have argued that use of
this technique avoids the undesirable effects of general or
neuraxial techniques, but no studies have established this.
Failure to produce complete local anesthesia/analgesia can
lead to increased stress response and/or myocardial isch-
emia.
B. Perioperative Pain Management
Patient-controlled intravenous and/or epidural analgesia is a
popular method for reducing postoperative pain. Several
studies suggest that effective pain management leads to a
reduction in postoperative catecholamine surges and hyper-
coagulability (66,67).
C. Intraoperative Nitroglycerin
There are insufficient data about the effects of prophylactic
intraoperative intravenous nitroglycerin in patients at high
risk (68–71). Nitroglycerin should be used only when the
hemodynamic effects of other agents in use have been
considered.
D. Transesophageal Echocardiography
There are few data on the value of transesophageal echo-
cardiography to detect transient wall motion abnormalities
in predicting cardiac morbidity in noncardiac surgical pa-
tients (72,73). Experience to date suggests that the incre-
mental value of this technique for risk prediction is small
(72). Guidelines for appropriate use of transesophageal
echocardiography have been published by the American
Society of Anesthesiologists and the Society of Cardiovas-
cular Anesthesiologists (74).
E. Perioperative Maintenance of Body Temperature
One randomized trial demonstrated a reduced incidence of
perioperative cardiac events in patients who were main-
tained in a state of normothermia via forced-air warming
compared with routine care (75).
VIII. PERIOPERATIVE SURVEILLANCE
A. Pulmonary Artery Catheters
Although very few studies that have been reported compare
patient outcomes after treatment with or without pulmonary
artery catheters, 3 variables are particularly important in
assessing benefit versus risk of pulmonary artery catheter
use: disease severity, magnitude of anticipated surgery, and
practice setting (76). The extent of expected fluid shifts is a
primary concern. Patients most likely to benefit from
perioperative use of a pulmonary artery catheter appear to be
those with a recent MI complicated by HF, those with
significant CAD who are undergoing procedures associated
with significant hemodynamic stress, and those with systolic
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or diastolic left ventricular dysfunction, cardiomyopathy,
and/or valvular disease who are undergoing high-risk oper-
ations.
B. Intraoperative and
Postoperative ST-Segment Monitoring
Intraoperative and postoperative ST changes indicating
myocardial ischemia are strong predictors of perioperative
MI in patients at high risk who undergo noncardiac surgery
(77–80). Similarly, postoperative ischemia is a significant
predictor of long-term risk of MI and cardiac death (81).
Conversely, in patients at low risk who undergo noncardiac
surgery, ST depression may occur and often is not associated
with regional wall-motion abnormalities (82–84). Accumu-
lating evidence suggests that proper use of computerized
ST-segment analysis in appropriately selected patients at
high risk may improve sensitivity for myocardial ischemia
detection.
C. Surveillance for Perioperative MI
Few studies have examined the optimal method for diag-
nosing a perioperative MI. Clinical symptoms, postopera-
tive ECG changes, and elevation of the MB fraction of
creatine kinase (CK-MB) have been studied most exten-
sively. Recently, elevations of myocardium-specific enzymes
such as troponin-I, troponin-T, or CK-MB isoforms have
also been shown to be of value (85–90). In patients with
known or suspected CAD who are undergoing high-risk
procedures, ECGs obtained at baseline, immediately after
surgery, and on the first 2 days after surgery appear to be
cost-effective (91). A risk gradient can be based on the
magnitude of biomarker elevation, the presence or absence
of concomitant new ECG abnormalities, hemodynamic
instability, and quality and intensity of chest pain syndrome,
if present. Use of cardiac biomarkers is best reserved for
patients at high risk and those with clinical, ECG, or
hemodynamic evidence of cardiovascular dysfunction.
IX. POSTOPERATIVE AND LONG-TERM MANAGEMENT
Despite even optimal perioperative management, some
patients will have perioperative MI, which is associated with
a 40% to 70% mortality rate (92). For patients who
experience a symptomatic perioperative ST-segment–
elevation MI as a result of sudden thrombotic coronary
occlusion, angioplasty should be considered after the risks
versus benefits have been weighed. Pharmacological therapy
with aspirin should be initiated as soon as possible, and a
beta-blocker and angiotensin converting enzyme inhibitor
may also be beneficial. Perioperative MI carries a high risk
for future cardiac events. Patients who sustain acute MI in
the perioperative period should receive careful medical
evaluation for residual ischemia and overall left ventricular
function.
It is also appropriate to recommend secondary risk
reduction in the relatively large number of elective surgery
patients in whom cardiovascular abnormalities are detected
during preoperative evaluations. Although the occasion of
surgery is often taken as a specific high-risk time, most of
the patients who have known or newly detected CAD
during their preoperative evaluations will not have any
events during elective noncardiac surgery. After the preop-
erative cardiac risk has been determined by clinical or
noninvasive testing, most patients will benefit from phar-
macological agents to lower low-density lipoprotein choles-
terol levels, increase high-density lipoprotein levels, or both.
On the basis of expert opinion, the goal should be to lower
the low-density lipoprotein level to less than 100 mg per
deciliter (2.6 mmol per deciliter) (93–95).
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